© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
First KRAS targeted therapy shows promise for lung and colon cancer
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
I understand how people dealing with a cancer diagnosis are incredibly overwhelmed with information.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
Multiple immune cell types must be present in tumors for checkpoint inhibitor therapies to be effective.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
